Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is for biosolutions startups to scale up.

⭐️ ABOUT THE SPEAKER

Claus first joined Novozymes in 1993 and led its R&D both in Denmark and the US, with six years as CSO. He has a Master’s degree in biochemistry and an MBA.

🔗 LINKS MENTIONED

• Novonesis’ website — https://www.novonesis.com/en
• Merger of Novozymes and Chr Hansen — https://www.novonesis.com/en/news/novozymes-and-chr-hansen-announce-name-future-combined-company-novonesis
• Novonesis’ nine-month results in 2025 — https://backend.novonesis.com/sites/default/files/document/2025-11/2025_46_9M_Interim_report.pdf
• Novonesis and Benchling partnership in 2024 — https://www.benchling.com/news/novonesis-and-benchling-long-term-partnership-to-power-rd
• EU biosolutions — https://research-and-innovation.ec.europa.eu/research-area/environment/bioeconomy/bio-based-products-and-processes_en

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/claus-crone-fuglsang-novonesis-biosolutions/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

• Newsletter: http://eepurl.com/h_fnmH
• LinkedIn: https://www.linkedin.com/company/flot-bio/
• X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

• [00:00:00] Intro
• [00:02:19] Novonesis: the Novozymes and Chr Hansen merger
• [00:09:51] Under the consumer radar
• [00:12:52] Business divisions and myriad applications
• [00:20:46] The scaling challenge in biosolutions
• [00:27:39] Novonesis’ profitability and growth
• [00:36:34] Genetic engineering and cool patents
• [00:47:57] Novonesis’ growing AI use
• [00:56:34] Claus Crone Fuglsang’s enthusiasm for his work
• [01:00:09] Industrial biotech globally
• [01:04:15] Quick-fire questions